Genprex partners with US CDMO for diabetes gene therapy manufacturing scale-up

Genprex, Inc.

On Aug 18, 2026, Genprex entered a development/manufacturing agreement with a leading US-based CDMO.
Agreement transitions AAV-based diabetes candidate from research-grade to clinical/commercial cGMP production.
CDMO will supply drug product for IND-enabling preclinical studies and future clinical trials.
Program targets T1D and T2D by delivering Pdx1 and MafA genes via AAV; also exploring non-viral LNP approach.
Manufacturing roadmap includes process optimization, scale-up, analytical qualification, and GMP compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.